Crandell Addington, Chief Executive Officer, Chairman, and Director. Mr. Addington is a cum laude graduate from Southwestern University, Georgetown, Texas, majoring in economics and accounting. Mr. Addington received post-graduate education in various sciences at Trinity University, San Antonio, Texas. Mr. Addington has, over the course of 40 years, founded and/or operated successful enterprises ranging from chemical manufacturing to oil and gas exploration, development, and production. Mr. Addington is also President and Chairman of the Board of Anviram, Inc. As a result of his prior and current corporate leadership positions, Mr. Addington has been responsible, among other duties, for interacting with biomedical researchers and clinicians both in the United States and Latin America.
Lou Kost, Jr., President, Secretary and Director. Mr. Kost attended the University of Texas at Austin, and St. Mary's University in San Antonio, Texas, where he studied marketing and financial management. Mr. Kost has been at various times a venture capitalist and management consultant. Mr. Kost is a former Texas state representative who served on the Banking Committee. Mr. Kost is currently a Director and Secretary of Anviram, Inc. Among other duties, Mr. Kost is responsible for interacting with investment bankers and the shareholders of the Company.
Robert A. Newman, Ph.D., Chief Science Officer, Chairman of the Scientific Advisory Board, and Director. Dr. Newman obtained his M.S. and Ph.D. degrees in Pharmacology and Toxicology from the University of Connecticut and then served in postdoctoral positions at the Medical School of the University of Georgia as well as the Department of Biochemistry at the University of Vermont. He served as a faculty member at the University of Vermont Medical School for seven years and then spent a sabbatical year at Stanford University performing research on immune targeted therapy. He spent 24 years at the University of Texas M. D. Anderson Cancer Center (MDACC) in Houston, Texas where he held the D. B. Lane Distinguished Professorship Chair. At MDACC he served as the founder and Co-Director of the Pharmaceutical Development Center and the institution's Analytical Center. He has published over 320 articles dealing with the preclinical and clinical pharmacology, toxicology and development of therapies for the prevention and treatment of malignant diseases.
Andrew Whitney, Vice Chairman and Director. Andrew is a Cambridge postgraduate-educated strategy specialist with experience at senior executive level in multiple technology sectors. Ex-Bain & Co consulting, ex-Bain Leveraged Buyout practice, and with private equity turnaround experience at management board level. He has 20 years’ experience as an entrepreneur, CEO, Founder and private equity investor in the bioinformatics, materials, energy, automotive, cleantech, digital media, blockchain and defense/aerospace sectors. Andrew also has 25 years’ experience in the licensing and management of IP rights, and developed initiatives with value of in excess of $350M for one particular client.
Andrew has served as an advisor to the board of several high profile, innovative businesses, both public and private. Andrew typically works directly with the CEO to develop strategy then create and/or accelerate the revenue road map through best-in-class partnerships for sector dominance. Past and present advisory clients include advanced materials, automotive, digital, energy, cleantech, aerospace & defense companies, and government clients, plus multiple entities in the blockchain sector.
Andrew maintains an extensive global network of high-level relationships, is known for his ability to commercialize cutting edge technologies and specializes in identifying, initiating and closing international commercial transactions.
He is active in the private equity space across a series of technology-driven deals and is currently focused on next generation communications and infrastructure solutions around 5G, power, water and waste management, and believes that new technologies can be transformative for quality of life and entire economies when properly integrated and implemented.
Andrew’s skills, capabilities and interests stretch beyond the traditional private equity model into identifying and implementing effective strategies to achieve commercial success, then optimizing organizational design to drive valuation. He has strong leadership skills and believes that success is ultimately a function of solid strategy, effective motivation, integrity and a focus on results in the absence of ego.
Mike Lindell, Director. Mike’s quintessentially American “rags-to-riches” story has inspired millions of people with its extraordinary journey of faith, hope, trust, resiliency, and redemption.
Mike was born in Minnesota in 1961 and almost immediately set out on an entrepreneurial path. He started many businesses from scratch and built them into successes. In 2004, he had a dream about inventing a pillow, which despite numerous setbacks, he turned into the now nearly $1 billion company, MyPillow.
Simultaneously, he was also imprisoned in the darkness of crack cocaine and alcohol addiction, which was destroying his entire life. At one point, the addictions became so severe that his crack cocaine dealers intervened, refusing to sell him any more drugs lest he die. One night in 2009, at the end of his rope, he prayed to God to remove his desire for drugs and alcohol, and the next morning, that desire was gone.
He has used the platform of trust and integrity to change the lives of those in need. Mike has a special knack for treating each of his employees as though they’re the most important person on earth, and that interpersonal gift spills over into all areas of his life. He knew MyPillow was just a platform for God, and he has followed his calling to help people.
Mike lives his life by his favorite Bible verse: “Trust in the Lord with all your heart and lean not on your own understanding; in all your ways submit to him, and he will make your paths straight.” Proverbs 3: 5–6
Jeffrey Thompson, Director. Mr. Thompson is an early investor who was asked to serve as the company's first outside director when Phoenix was formed in 2003. He is an attorney and currently lives in Des Moines, Iowa. He is employed with the Iowa Department of Justice, where he serves as Deputy Attorney General. Prior to his appointment to this position in 2008, Mr. Thompson was in private practice and specialized in civil litigation.
Andrew J. Butler, Director. Mr. Butler is Vice Chairman of Cottingham & Butler, Inc. and President of SISCO and HealthCorp. Prior, he was Chief Executive Officer and President of both Butler Insurance Service, Inc. and Butler Benefit Service, Inc. He is currently a Trustee of Junior Achievement of the Heartland and on the board of the Dubuque Museum of Art. He has served as the President of the Board of Trustee’s for the Figge Art Museum, was a Director for the Third Party Administrators of America Association (TPAAA), and has service in an advisory capacity to several public and privately held organizations for both product development and managerial development matters. He earned his MBA from The College of Insurance in New York City, his BS in Finance from Babson College and holds several industry designations, Including CPCU, CEBS, CSFS, and ARM.
Macdonald T. Haskell, Director. Mr. Haskell is President of MTH Ventures, Inc., a company primarily involved in private investments and entrepreneurial endeavors. Mac began his career in New York at Merrill Lynch and Co. and earned his B.A. in Economics from Hobart College in 1980.
Rick Matos, Ph.D., Director. Dr. Matos has over thirty-two years of experience in the pharmaceutical arena as researcher, patent practitioner and consultant and over twenty-seven years of experience as a patent practitioner. He is an author of scientific articles and an inventor of pharmaceutical and chemical process technologies.
By integrating IP, business, R&D, regulatory, and commercialization strategies and by building and managing robust large patent portfolios, he has helped client startup corporations raise capital and achieve valuations of tens to hundreds of millions of dollars before being sold or even going public. Many domestic and international pharmaceutical products are covered by patents he has prosecuted. Dr. Matos earned his doctorate in Bioorganic Chemistry from Texas A&M University after having completed his studies on the chemical and enzymatic synthesis of penicillin, amino acids and other natural products. He worked for The DuPont Merck Pharmaceutical Company as a Senior Research Scientist primarily on biotech large-scale process development and drug discovery in many therapeutic areas while advancing to Project Team Leader within the R&D department. After helping establish the pharmaceutical IP practice in the Dallas office of a major firm, Dr. Matos founded Innovar, L.L.C. in March of 2000.